Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 5Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 20pembrolizumab 19Nivolumab 10fludarabine 7Radiosurgery 7Specimen Handling 6Ipilimumab 6Injections 5Celecoxib 5poly ICLC 4Radiation 4Paclitaxel 4Melphalan 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Docetaxel 4Cryosurgery 4durvalumab 3cemiplimab 3Filgrastim 3Etoposide 3Cisplatin 3Blood Specimen Collection 3Biopsy 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2bempegaldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × resiquimod × Sarcoma × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡